AI Article Synopsis
- The K-ABC study investigates the health effects of atomic bomb exposure on Korean survivors and their descendants to see if these impacts are genetically inherited.
- From 2020 to 2024, 2,544 participants were involved, including 1,109 atomic bomb survivors (G1), their children (G2), and grandchildren (G3), with 71.9% completing health assessments and surveys.
- The study collected exposure data through questionnaires and official records, while disease prevalence was assessed based on self-reported physician diagnoses, laying the groundwork for future research results.
Article Abstract
The Korean Atomic Bomb Survivor Cohort (K-ABC) study was designed to investigate the health impacts of atomic bomb exposure on Korean survivors and to explore whether these effects are passed down genetically to their descendants. This paper outlines the study's design, data collection methods, baseline socio-demographic characteristics, exposure status, and disease prevalence among the participants, based on survey responses and health examinations. From 2020 to 2024, a total of 2,544 individuals, comprising 1,109 atomic bomb survivors (G1), 1,193 children of G1 (G2), and 242 grandchildren of G1 (G3), consented to participate in the study. Of these, 1,828 participants (659 in G1, 927 in G2, and 242 in G3) completed the survey and underwent health examinations, representing a participation rate of 71.9%. Exposure information was gathered using a questionnaire and verified through records from the Korean Red Cross and a handbook issued by the Japanese government. Disease prevalence was determined based on participants' self-reported physician diagnoses. This study presents details about the K-ABC study and provides baseline data on the participants recruited. These data will be valuable for interpreting the results of future K-ABC studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4178/epih.e2024089 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Growth inhibition and toxicity assessments of cis-3,4-diaryl-α-methylene-γ-butyrolactams in cultured human renal cancer cells and zebrafish embryos.
Biochim Biophys Acta Gen Subj
January 2025
Department of Chemistry, Tamkang University, 151, Yingzhuan Road, Danshui Dist., New Taipei City 25137, Taiwan. Electronic address:
This study aimed to compare and evaluate the growth inhibition effects of eight previously synthesized compounds, cis-3,4-diaryl-α-methylene-γ-butyrolactams (compounds 1-8), on two human renal carcinoma cell (RCC) lines: CRL-1932 (rapid growth) and HTB-44 (slow growth). MTT assays and flow cytometry were conducted, revealing that compounds 5 and 6 had the potential to induce cell death in the slow-growing RCC cells (HTB-44), while compound 8 demonstrated effectiveness in both RCC lines (HTB-44 and CRL-1932). Additionally, a non-transformed HEK293 cell line and a transgenic zebrafish with a green fluorescent kidney Tg(wt1b:egfp) were used to assess the toxicities of compounds 5, 6, and 8.
View Article and Find Full Text PDFArterial Thromboembolism in Patients With Advanced Lung Cancer: Secondary Analyses of the Rising-VTE/NEJ037 Study.
Cancer Med
January 2025
Division of Medical Oncology and Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
Background: Cancer-associated thromboembolism has been thoroughly investigated in previous studies, and direct oral anticoagulants (DOACs) were established for the treatment and prevention of venous thromboembolism (VTE). However, the risks of cancer-associated arterial thromboembolism (ATE) and the efficacy of DOACs remain unclear.
Objectives: To evaluate the risk factors and the clinical activity of edoxaban (EDO) for the prevention of ATE in patients with advanced lung cancer.
I-β-Methyl Iodophenyl Pentadecanoic Acid and Thallium Dual Myocardial Single-Photon Emission Computed Tomography (BMIPP/Tl SPECT) Detects Coronary Microvascular Dysfunction in a Patient With Antiphospholipid Syndrome Nephropathy.
Circ J
January 2025
Department of Radioisotope Medicine, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University.
Plutonium Marker for the Great Acceleration by Intensified Human Activities.
Environ Sci Technol
January 2025
Xi'an AMS Center, State Key Laboratory of Loess Science, Shaanxi Key Laboratory of Accelerator Mass Spectrometry Technology and Application, Institute of Earth Environment, Chinese Academy of Sciences, Xi'an 710061, P. R. China.
There has been a sharp rise in the extent and scale of human activities since the mid-20th century, termed the "Great Acceleration", and nuclear activities are one of the defining technological processes for this period. Pu released by atmospheric nuclear weapons tests provides an ideal chronostratigraphic marker for labeling this change due to its global fallout feature, temporal mutation, and long half-lives. However, the accumulation dynamics of plutonium from atmospheric deposition to preservation in the sediment is still controversial.
View Article and Find Full Text PDFAdjunctive effects of eltrombopag on immunosuppressive therapy for childhood aplastic anemia.
Int J Hematol
December 2024
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Eltrombopag is used with first-line immunosuppressive therapy for adult aplastic anemia, although its practical utility in childhood remains unclear. We retrospectively analyzed the outcomes of pediatric patients who received eltrombopag in Japan. Of the 27 eligible patients, 23 (85%) were previously treated, and 15 (56%) had severe or very-severe disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!